Pulse Biosciences (NASDAQ:PLSE) Cut to Sell at Wall Street Zen

Pulse Biosciences (NASDAQ:PLSE) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

PLSE has been the topic of several other research reports. BTIG Research assumed coverage on shares of Pulse Biosciences in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price objective on the stock. Mizuho set a $65.00 price objective on Pulse Biosciences in a research note on Friday. Needham & Company LLC upped their price objective on Pulse Biosciences from $58.00 to $64.00 and gave the stock a “buy” rating in a research report on Friday. Canaccord Genuity Group lifted their price target on shares of Pulse Biosciences from $58.00 to $74.00 and gave the company a “buy” rating in a research report on Friday. Finally, Freedom Capital upgraded Pulse Biosciences to a “strong-buy” rating in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.60.

Pulse Biosciences Trading Up 0.4%

NASDAQ PLSE opened at $53.29 on Friday. Pulse Biosciences has a 12-month low of $12.56 and a 12-month high of $58.90. The company has a 50 day moving average price of $51.55 and a two-hundred day moving average price of $32.28.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.52 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The firm’s quarterly revenue was down 54.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.29) earnings per share. As a group, analysts anticipate that Pulse Biosciences will post -1.34 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Liane Teplitsky purchased 1,001 shares of the stock in a transaction on Tuesday, September 1st. The shares were purchased at an average cost of $49.95 per share, with a total value of $49,999.95. Following the acquisition, the chief operating officer directly owned 4,095 shares in the company, valued at $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders purchased 4,095 shares of company stock valued at $199,931. Insiders own 74.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC increased its holdings in Pulse Biosciences by 844.6% during the 3rd quarter. Sterling Capital Management LLC now owns 614 shares of the company’s stock valued at $31,000 after purchasing an additional 549 shares during the period. Osterweis Capital Management Inc. bought a new stake in Pulse Biosciences during the second quarter worth approximately $28,000. Axxcess Wealth Management LLC bought a new position in Pulse Biosciences in the 3rd quarter worth about $242,000. Bender Robert & Associates bought a new stake in Pulse Biosciences during the 3rd quarter valued at $379,000. Finally, Jupiter Topco LLC acquired a new position in Pulse Biosciences during the 2nd quarter valued at approximately $241,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Trending Headlines about Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
• Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
• Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
• Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
• Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.